Simple response is that Arovella's CAR-iNKT cell therapy model will be less expensive and more scalable, while also potentially succeeding in a broader range of cancer applications, including solid tumors.
Chimeric's CAR-T therapies are currently well-established in treating hematologic cancers, but may face more challenges in terms of cost and scalability.
However, both models could co-exist, excelling in different cancer types or patient needs. Im leaning towards an ALA (script) TO, and probably why they haven't given Jen the CEO role yet.
Ann: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete, page-64
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $19.57K | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 419507 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18587873 | 22 |
View Market Depth
| Last trade - 15.59pm 27/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |